News
Bio-Link's annual Summer Fellows is an opportunity for biotechnology educators to gather together and learn about biotechnology education. For more...
Amgen Inc. has secured the right to sell a copycat version of AbbVie's top-selling drug in the U.S. — but first, it will have to wait six years.
Six years after the first antibody-drug conjugate (ADC) was pulled from the market, the pipeline is once again filled with an array of potent new...
Join Bio-link's webinar series to learn about Genome engineering with CRISPR-cas9, Exploring Career Opportunities in Biotechnology, 4 year...
Bio-Link webinar series. Webinar topics include: Understanding CRISPR/Cas 9 and Genome Editing, Interactive movie dessigned for teaching concepts in...
The European Commission (EC) granted marketing authorization in the European Union (EU) for FLIXABI ®, an infliximab biosimilar referencing Remicade...
